PAVM PAVmed Inc.

NEUTRAL Impact: 4/10 S-3
Horizon months Filed Apr 21, 2026 Processed 1mo ago SEC 0001493152-26-018158
Shelf registration — potential dilution
Latest settled — T+20d
PAVM ▼ -32.09% at T+20d
NEUTRAL call ✗ call lost -32.09% · α vs SPY -37.01% · entry $9.15 → $6.21
Next anchor: T+60d in 5w
Currently $4.68 · -48.82% from $9.15 entry
Entry anchored
Apr 20, 12:33 PM ET
via Databento tick
T+1d
+2.46%
call +2.46% · α +1.44%
$9.37
settled 7w ago
T+5d
-2.24%
call -2.24% · α -3.33%
$8.94
settled 6w ago
T+20d
-32.09%
call -32.09% · α -37.01%
$6.21
settled 23d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

PAVmed Inc. has filed an S-3 shelf registration to register 9,230,786 shares of common stock for resale by selling stockholders. These shares originated from a February 2026 private placement of Series D convertible preferred stock and warrants, which were converted into common stock in March 2026. The company will not receive proceeds from the resale of these shares but could receive up to $30 million if the warrants are exercised. This registration facilitates future liquidity for investors but does not raise new capital for the company.

Key Financial Metrics

Offering Size
$84.8M
Dilution
77.7%

Actionable Insight

Monitor warrant exercise activity, as the potential $30 million in proceeds could improve the company's financial position. The resale of shares by selling stockholders may increase trading volume and potentially impact stock price volatility.

Key Facts

  • PAVmed filed an S-3 shelf registration to register 9,230,786 shares of common stock for resale by selling stockholders.
  • The shares originated from the conversion of 30,000 shares of Series D convertible preferred stock into 4,615,393 common shares, plus 4,615,393 shares issuable upon warrant exercise.
  • The company will not receive proceeds from the resale of these registered shares.
  • The company may receive up to $30 million if the outstanding warrants are exercised.
  • The registration supports investor liquidity but does not represent a new capital raise for the company.

Financial Impact

The company could receive up to $30,000,000 if all warrants are exercised. The resale of 9,230,786 shares by selling stockholders will not provide proceeds to the company.

dilutionliquiditycapital structure

Risk Factors

  • Potential dilution if warrants are exercised
  • Increased stock price volatility from selling stockholder activity
  • No proceeds to company from resale of registered shares

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001493152-26-018158
Exhibit: ex10-1.htm0001493152-26-018158
Exhibit: ex107.htm0001493152-26-018158
Exhibit: ex5-1.htm0001493152-26-018158
Exhibit: ex23-2.htm0001493152-26-018158
Exhibit: ex23-1.htm0001493152-26-018158
Document: 0001493152-26-018158-index-headers.html0001493152-26-018158
Document: 0001493152-26-018158-index.html0001493152-26-018158
Document: 0001493152-26-018158.txt0001493152-26-018158
2 reports for PAVM
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PAVM — sortable, filterable
Type Now
May 15, 2026
25d ago
8-K
BEARISH ★ 6/10
$6.53 $6.39▲ +2.14%▲ +3.11%$4.68 (+28.33%)
Apr 21, 2026
7w ago
S-3
NEUTRAL ★ 4/10
$9.15 $8.94▼ −2.24%▼ −3.33%$4.68 (−48.82%)
Showing 2 of 2

US Market Status

Market Closed — Opens Thu (11h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access